Specifically, we propose CX-5461 will have efficacy in HR-deficient HGSOC and in HGSOC tumours with elevated MYC activity such as the high-MYCN HGSOC subtype associated with poor prognosis26,44. This evidence concerns the gene MYC and neoplasm.